coloscopy uc early stage hyperemia petechial bleeding fragiability
TRANSCRIPT
COLOSCOPYCOLOSCOPYUC Early StageUC Early Stage
HyperemiaHyperemiaPetechial Petechial
BleedingBleeding FragiabilityFragiability
COLOSCOPYCOLOSCOPYCD Early StageCD Early Stage
AphtoidAphtoidMucosal Mucosal
LesionsLesions
(Ulcers)(Ulcers)
COLOSCOPYCOLOSCOPYUC Floride (Acute) StageUC Floride (Acute) Stage
ConfluatingConfluating(Continious)(Continious)
UlcerationsUlcerationsPseudopolypoPseudopolypo
sissis
COLOSCOPYCOLOSCOPYCD Floride (Acute) StageCD Floride (Acute) Stage
Couble-stone Couble-stone reliefrelief
FissuraFissuraFistulaFistulaSolitary ulcersSolitary ulcers
COLOSCOPYCOLOSCOPYUC Late (chronic) StageUC Late (chronic) Stage
PseudopolypsPseudopolypsLoss of haustraLoss of haustraCarcinomaCarcinoma
COLOSCOPYCOLOSCOPYCD Late (chronic) StageCD Late (chronic) Stage
StenosisStenosisFistulaFistulaPseudopolypsPseudopolypsDiverticulaDiverticula
Radiology / Radiology / CDCD
Couble stoneCouble stoneAphtoid ulcersAphtoid ulcersPseudodiverticulaPseudodiverticulaFistulaFistulaPolymorph ulcersPolymorph ulcers
Activity IndexActivity Index
BasedonBasedon - Clinical Activity- Clinical Activity
- Endoscopical Activity- Endoscopical Activity
- Histological Activity- Histological Activity
- Laboratory Activity- Laboratory Activity
Activity Index /CDActivity Index /CD
Activity Index /UCActivity Index /UC
Differential DiagnosisDifferential Diagnosis
Prognosis / UCPrognosis / UC
80% chronic intermittant80% chronic intermittant15% chronic continious15% chronic continious10% acute fulminant10% acute fulminant
The longer the chronicityThe longer the chronicityThe worse is the prognosis.The worse is the prognosis.
Prognosis / CDPrognosis / CD
“ “ No absolute cure”No absolute cure” MILDMILD MODERATEMODERATE 30% Remission30% Remission İn 1 yearİn 1 year 70% Remission 70% Remission In 2 yearsIn 2 years 50% Remission 50% Remission• 70% - Surgical Intervention70% - Surgical Intervention
POSTOPPOSTOP RefallRefall 1 year 70%1 year 70%2 years 50%2 years 50%
Summary -Prognosis / UCSummary -Prognosis / UC
High Rezidive – QuotientHigh Rezidive – Quotient Good if isolated Procto- Good if isolated Procto-
sigmoiditissigmoiditis Pancolitis Pancolitis HIGH – RiskHIGH – Risk PancolitisPancolitis often OP.often OP.
Summary - Prognosis / CDSummary - Prognosis / CD
High – Rezidive QuotientHigh – Rezidive Quotient Complications Complications OPOP
Goals of Therapy for IBDGoals of Therapy for IBD
Inducing remissionInducing remission Maintaining remissionMaintaining remission Restoring and maintaining nutritionRestoring and maintaining nutrition Maintaining patient’s quality of lifeMaintaining patient’s quality of life Surgical intervention (selection of optimal time Surgical intervention (selection of optimal time
for surgery)for surgery)
Pharma-InformationPharma-Information
1)1) Oral AminosalicylatesOral Aminosalicylates2)2) Topical AminosalicylatesTopical Aminosalicylates3)3) CorticosteroidsCorticosteroids4)4) ImmunsuppressivaImmunsuppressiva5)5) AntibioticsAntibiotics6)6) Biologic agents (anti TNF-alfa)Biologic agents (anti TNF-alfa)
Oral AminosalicylatesOral AminosalicylatesA.A. SULFASALACINSULFASALACIN COLONCOLON
- Sulfapyridine – - Sulfapyridine – CarrierCarrier++- 5-ASA- 5-ASA – Antiinflammatuar – Antiinflammatuar
5-ASA :5-ASA : 3-6 g/d 3-6 g/d INHIBITIONINHIBITION - cyclooxygenase- cyclooxygenase - lipooxygenase- lipooxygenase O2-Radical O2-Radical - neutrophil - neutrophil Clearance Clearance NK-ABsynthesisNK-ABsynthesis depressiondepression
SulfasalacinSulfasalacin
SulfapyridineSulfapyridine - AZO-BINDING- - AZO-BINDING- 5-ASA 5-ASA
AzoreductaseAzoreductase
COECUMCOECUM
Oral AminosalicylatesOral Aminosalicylates
B. MESALAMIN B. MESALAMIN IleumIleum 5-ASA5-ASA ColonColon2 g/d2 g/d EudragitEudragitCapselCapsel
Topical AminosalicylatesTopical Aminosalicylates
5-ASA – FOAM5-ASA – FOAM
SUPPOSITOIRESSUPPOSITOIRES
CORTICOSTEROIDSCORTICOSTEROIDS
ORALORALIVIV useuseTOPICALTOPICALPrednisonePrednisone 60/50/40......10 mg60/50/40......10 mg
OrOrLess side effected new formsLess side effected new formsBudesonidBudesonid 9 mg/d9 mg/d(Endocort / Budenofalk(Endocort / Budenofalk))
CORTICOSTEROIDSCORTICOSTEROIDS
Inhibition of :Inhibition of : Proinflammatory Proinflammatory CytokinesCytokines
Supportion of protective CK. Supportion of protective CK. (IL-4, IL 10)(IL-4, IL 10)
Inhibition of Inflammation MediatorsInhibition of Inflammation Mediators(PAF)(PAF)
Corticosteroids in CD:Corticosteroids in CD:Induction of RemissionInduction of Remission
*Randomized controlled trial†Multicenter prospective trial
Malchow H et al. Gastroenterology. 1984;86:249.Modigliani R et al. Gastroenterology. 1990;98:811.
Summers RW et al. Gastroenterology. 1979;77:847.
Clinical Remission
% P
atie
nts
30%
82%*
38%
p not calculated 92%†
60%*
17 weeks 18 weeks 7 weeksNCCDS ECCDS GETAID
0
20
40
60
80
100 CorticosteroidsPlacebo
Remission Rates in Acute Crohn’s StudiesRemission Rates in Acute Crohn’s Studieswith Budesonide CIRwith Budesonide CIR
Bud CIRBud CIR Bud CIRBud CIR PlaceboPlacebo Pentasa Pentasa®® Prednisolone Prednisolone 9 mg QD9 mg QD 4.5 mg BID4.5 mg BID 2 g BID2 g BID 40 mg 40 mg
Remission rates atRemission rates at8 weeks (%)8 weeks (%)
Greenberg 1994; Rutgeerts 1994; Thomsen 1998
0
10
20
30
40
50
60
70
ImmunsuppressivaImmunsuppressivaA.A. Azathiopyrin (AZT)Azathiopyrin (AZT)6-Mercaptopurin6-Mercaptopurin- Cell replication ]- Cell replication ]B.B. Methotrexat (MTX)Methotrexat (MTX)- Antimetabolite- Antimetabolite- Inhibition of- Inhibition of Dihydrofolacid reductaseDihydrofolacid reductase++ Lymphocytic ProliferationLymphocytic ProliferationC.C. CyclosporinCyclosporin- Immunmodulater- Immunmodulater- T-Cell depression- T-Cell depression
AntibioticsAntibiotics
• MetronidazolMetronidazol
Therapeutic PyramidTherapeutic Pyramidfor Active Crohn’s Diseasefor Active Crohn’s Disease
SevereSevere
ModerateModerate
Aminosalicylates/AntibioticsAminosalicylates/Antibiotics
CorticosteroidsCorticosteroids
ImmunomodulatorsImmunomodulators
SurgerySurgery
InfliximabInfliximab
??(Prednisone)(Prednisone)
MildMild
(Budesonide)(Budesonide)
Outcomes for Mild-Moderate DiseaseOutcomes for Mild-Moderate Disease
Mild-Moderate Disease
AminosalicylateResponse 40-50%
Antibiotic(Colonic Disease)Response 40-50%
Budesonide(Ileum-Right Colon)Response 50-65%
PlaceboResponse 30-40%
Biologic agentsBiologic agents
•İnfliximapİnfliximap•adaluminapadaluminap
Infliximab: Mechanism of Infliximab: Mechanism of ActionAction
Healing of Colonic UlcerationHealing of Colonic Ulcerationwith Infliximabwith Infliximab
Van Dullemen HM et al. Gastroenterology 1995;109:129-135
PretreatmentPretreatment 4 weeks 4 weeks post-treatmentpost-treatment
REMICADEREMICADE®® (infliximab) in Patients with (infliximab) in Patients with Fistulizing Crohn’s DiseaseFistulizing Crohn’s Disease
Complete Response: All Fistulas ClosedComplete Response: All Fistulas Closed
P=0.001
P=0.04
*Placebo=Conventional Therapy*
Present, et al.
Present D, et al. N Engl J Med. 1999;340:1398-1405.
Incidence of Incidence of Antibodies-to-Infliximab (ATI) Antibodies-to-Infliximab (ATI) Maintenance Studies*Maintenance Studies*
Maintenance StudiesMaintenance Studies
% of Pts without ATI% of Pts without ATI% of Pts with ATI% of Pts with ATI % of Patients Inconclusive% of Patients Inconclusive††
* pts with evaluable samples* pts with evaluable samples
ACCENT I ACCENT I CDCD
n = 514n = 514Week 72Week 72
16
2758
ACCENT IIACCENT IICDCD
n = 258n = 258Week 54Week 54
17
52
31
ATTRACTATTRACTRARA
n = 295n = 295Week 102Week 102
9
56
36
Antibody-to-Infliximab (ATI) StatusAntibody-to-Infliximab (ATI) Status
†† pts with long-lasting serum concentrations of infliximab and never ATI (+)pts with long-lasting serum concentrations of infliximab and never ATI (+)
11
49
40
ASPIREASPIRERARA
n = 629n = 629Week 54Week 54
ASPIRE: Integrated Safety Summary, Sep. 18, 2003
InfliximabInfliximabInfliximab indicated
Exclude enteric pathogenExclude abscess, strictureExclude latent/active TB
Infliximab 5 mg/kg wks 0, 2, 6Consider steroid pre-treatmentConsider acetaminophen,
diphenhydramine pre-treatment
Infliximab 10 mg/kg
Surgery or investigational Rx
Observe up to 8 wks
Recurrent sx≤ 4 wks
Recurrent sx> 4 - < 8 wks
Recurrent sx≥ 8 wks
Response
Maintain infliximab5 mg/kg q 4-8 wks
Inadequate response Escalate dose or
shorten intervalMaintain infliximab5 mg/kg q 8 wksLoss of
response
Inadequate response
Inadequate response
(Start 6-MP/AZA or MTX)
Medical Management / CDMedical Management / CD
Long-term Therapy :Long-term Therapy :
AA – IMMUNSUPPRESSIVA – IMMUNSUPPRESSIVAA2T :A2T : 25/50 MG Tbl25/50 MG Tbl..++- CS- CSfor Relapsing Fallsfor Relapsing Falls
B – B – SURGERYSURGERYRemissions – Remissions – maintenancemaintenance
- 5.ASA :- 5.ASA : 2 g/d 2 g/d 2 years2 years
MethotrexateMethotrexate
Historical OverviewHistorical Overview1948 1948 –– first “designer drug” specific first “designer drug” specific
antagonist of folic acidantagonist of folic acid1950’s 1950’s –– serendipitous discovery serendipitous discovery
of activity in psoriasisof activity in psoriasis1960’s 1960’s –– widely used for psoriasis widely used for psoriasis ––
hepatotoxichepatotoxic1966 1966 –– Enderlin reported use in RA Enderlin reported use in RA1985 1985 –– Wienblatt defines Wienblatt defines
pharmacokinetics in RApharmacokinetics in RA1980-2000 1980-2000 –– treatment of choice treatment of choice
for RAfor RA
Feagan. N Eng J Med. 1995;332(5):292-7
% R
espo
nse
% R
espo
nse
0 0
25 25
19.1%19.1% 39.4%39.4%
P P =0.025=0.025
PlaceboPlacebo MTXMTX
5050
MTX Results: RemissionMTX Results: Remission
Methotrexate in IBD: ToxicityMethotrexate in IBD: Toxicity
MajorMajorHepaticHepaticMyelosuppressiveMyelosuppressivePulmonaryPulmonaryFertility-relatedFertility-relatedTeratogenicTeratogenicEnteritic/coliticEnteritic/colitic
Egan LJ, Sandborn WJ. Mayo Clin Proc 1996;71:69-80
MinorMinorGastrointestinalGastrointestinalAlopecia-inductiveAlopecia-inductiveAllergicAllergicNeurologicNeurologic
CD: Moderate to SevereCD: Moderate to SevereModerate CD
Observe TaperSuccess
PO Steroids
6-MP/AZA
Consider change to MTX
Add infliximab
Surgery or investigational
therapy
Severe CD
IV Steroids
Adequate response
Inadequate response
Consider infliximab+ 6-MP/AZA or MTX
Consider surgery
Adequate response
Failure
Maintain6-MP/AZA or MTX
Maintaininfliximab +
6-MP/AZA or MTX
Adequate response
Adequate response
Adequate response
Inadequate response
Inadequate response/intolerant
Inadequate response/intolerant
Inadequate response/intolerant
Medical Management / UCMedical Management / UC
Refractory States or Chronic Refractory States or Chronic active Formsactive Forms ImmunsuppressivaImmunsuppressiva
A2T :A2T :+ ?+ ?CsCsOPOP ProctocolectomyProctocolectomy
(= Definitive Cure)(= Definitive Cure)
Ulcerative ColitisUlcerative Colitis
Remissions – MaintenanceRemissions – Maintenance
5-ASA5-ASA 2 gr/d2 gr/d
OP – Indications / CDOP – Indications / CD
BleedingBleeding IleusIleusStenosisStenosisFistulaFistulaCarcinomCarcinomPerforationPerforationAbcessAbcess
OP – Indications / UCOP – Indications / UC
Toxic MegacolonToxic MegacolonPerforationPerforationSevere BleedingSevere Bleeding